Skip to main content

Table 2 Targeted gene alterations and drugs of the included studies for the meta analyses

From: Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Study

Targeted gene alteration

Detailed genotypes

Targeted drugs

CLCGP

EGFR mutations

Not shown

gefitinib, erlotinib

Molina-Vila

EGFR mutations

Not shown

erlotinib

Bria E

EGFR mutation

Exon 19 deletion;

Exon 21 L858R mutation

gefitinib

Canale M

EGFR mutation

Exon 19 deletion

Exon 21 L858R mutations

Exon 21 L861Q mutations

Exon 18 mutations

gefitinib,

erlotinib,

afatinib,

dacomitinib

Labbé C

EGFR mutation

Exon 19 deletion

Exon 21 L858R mutation

Exon 18 mutations,

Exon 19 insertion,

Exon 19 L747P mutation

Multiple mutations

(Exons 21 + 20, exons 19 + 20, exons 21 + 18)

gefitinib,

erlotinib

Vander Laan

EGFR mutation

Exon 19 deletions

Exon 21 L858R mutation

Exon 18 G719X mutation

Exon 20 insertions

Exon 20 S768I mutation

gefitinib,

erlotinib,

afatinib

Aisner

EGFR mutation

Exon 19 deletions

Exon 21 L858R mutation

Exon 18 G719X mutation

Exon 21 L861Q mutation

EGFR-TKIs

Tsui DWY

EGFR mutation

EGFR Exon 21 L858R mutations

gefitinib

HelenaA.Yu

EGFR mutation

EGFR T790M mutation

Exon 19 deletion

Exon21 L858R mutation

Exon 20 insertions

Exon 18 deletion

Exon 19 insertion

Exon21 L861Q mutation

Exon 18 G719X mutation

Exon 19 L747P. mutation

Exon 18 E709X mutation + Exon 18 G719X mutation

Exon 18 G719X+ Exon 20 S768I mutation

Exon 18 G719X+ Exon21 L861Q mutation

erlotinib

Youjin Kim

EGFR mutation

Exon21 L861Q mutation

Exon 19 deletion

Exon21 L858R mutation

Exon18 G719A mutation

Exon21 L833V mutation + Exon21 L858R mutation

Exon21 L833V+ Exon21 H835L mutation

gefitinib,

erlotinib,

afatinib,

osimertinib,

olmutinib

Rachiglio AM

EGFR mutation

Exon 19 deletion

Exon21 L858R

Exon20 T790M

gefitinib,

erlotinib,

afatinib,

Kron A

ALK re-arrangements

EML4-ALK fusions

crizotinib,

ceritinib,

alectinib,

brigatinib

Yu Y

ALK re-arrangements

EML4-ALK fusions

Non-EML4-ALK fusions

crizotinib

Christopoulos P

ALK re-arrangements

EML4-ALK fusions

KIF5B-ALK fusions

ALK-TKIs

Song P

ALK re-arrangements

EML4-ALK fusions

Non-EML4-ALK fusions

ALK-TKIs

  1. Abbreviations: EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, TKI Tyrosine kinase inhibitor